Part II. Measuring skin pain in humans: Quantitative, psychophysical, and patient-reported tools for dermatology.
Standardizing skin pain measurement tools can improve trial comparability and inform targeted therapy development in dermatology.
Where it sits
this study against the rest of the hcg (human chorionic gonadotropin) corpusSummary and findings
The article reviews tools for measuring skin pain in humans, focusing on quantitative sensory testing and patient-reported outcome measures. It synthesizes methods for assessing various pain thresholds and profiles in dermatologic conditions. The review highlights the need for standardization and validation across different diseases and populations.
Abstract
Quantifying skin pain is essential for dermatologic research and patient care. This Methods and Techniques in Skin Research article (part II) synthesizes human-focused tools spanning psychophysical and patient-reported measures. A standardized workflow for quantitative sensory testing (QST) outlines the measurement of thermal detection and pain thresholds, mechanical detection and pinprick pain, temporal summation, dynamic mechanical allodynia, vibration, and pressure; these techniques enable phenotyping of gain and loss of somatosensory function. Core patient-reported outcome measures (PROMs) such as the Numeric Rating Scale, Visual Analog Scale, and multidimensional instruments are summarized alongside disease-specific measures, with emphasis on recall periods, meaningful change thresholds, and adaptations for special populations when available. Disease-focused sections outline nociceptive (eg, atopic dermatitis, wounds), neuropathic (eg, polyneuropathy, postherpetic neuralgia), and mixed (eg, hidradenitis suppurativa) pain profiles, illustrating how pairing QST with PROMs enhances understanding. Objective markers such as evoked potentials, physiologic signals, and molecular biomarkers are reviewed, noting current limitations in standardization and clinical adoption. Future priorities include validation of tools across diseases and populations and the creation of guidelines for QST use in clinical dermatology. Together, these methods provide an actionable framework for harmonizing skin-pain measurement, improving trial comparability, and informing the development of targeted therapies.
Background
The study addresses the challenge of quantifying skin pain, a critical aspect of dermatologic research and patient care. Accurate measurement of skin pain is essential for understanding somatosensory function and developing targeted therapies. Existing methods include both psychophysical and patient-reported measures, but standardization and validation across diseases are needed.
Methods
This is a review article synthesizing existing tools for measuring skin pain in humans. It covers quantitative sensory testing methods such as thermal and mechanical detection, as well as patient-reported outcome measures like the Numeric Rating Scale. The review also discusses disease-specific pain profiles and the integration of objective markers.
Results
The review outlines a standardized workflow for quantitative sensory testing, covering various pain thresholds and profiles. It emphasizes the use of patient-reported outcome measures and the need for standardization of objective markers. The article identifies gaps in validation and clinical adoption, highlighting areas for future research.
Interpretation
The review provides a comprehensive overview of current tools for measuring skin pain, emphasizing the need for harmonization and standardization. While it offers valuable insights, the lack of original data limits its clinical applicability. The findings suggest that integrating quantitative sensory testing with patient-reported measures could enhance understanding of pain profiles.
Key findings
- Quantitative sensory testing measures thermal detection and pain thresholds.
- Patient-reported outcome measures include the Numeric Rating Scale and Visual Analog Scale.
- Disease-specific pain profiles are outlined for conditions like atopic dermatitis and polyneuropathy.
- Current limitations exist in standardization and clinical adoption of objective markers.
- Future priorities include validation of tools and creation of clinical guidelines.
Limitations
- No original data presented
- Reliance on existing literature
- Limited standardization of tools
- Lack of clinical adoption of objective markers